Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.
Katja Schindler
Honoraria - Bristol-Myers Squibb
Kaan Harmankaya
Honoraria - Bristol-Myers Squibb
Michael Andrew Postow
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Sophie Frantal
No relevant relationships to disclose
Danielle Bello
No relevant relationships to disclose
Charlotte Eielson Ariyan
Consultant or Advisory Role - Bristol-Myers Squibb
Olivier Alain Michielin
No relevant relationships to disclose
Christoph Hoeller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Hubert Pehamberger
Consultant or Advisory Role - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb